Modernavs.Neurocrine Biosciences
MRNA vs NBIX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Moderna is about 6.1× larger than Neurocrine Biosciences by market cap; year to date, Moderna leads (+568.0% vs −0.4%).
Side by side
| MRNA | NBIX | |
|---|---|---|
| Market cap | $88.6B | $14.4B |
| Price | $225.00 | $142.44 |
| Today | +14.2% | +0.8% |
| Return YTD | +568.0% | −0.4% |
| Return 1Y | +605.6% | +1.6% |
| Since June 26, 2026 | +234.5% | −15.5% |
| P/E | — | 20.5 |
| P/S | 39.8 | 4.3 |
| P/B | 13.1 | 3.9 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
ModernaMRNA
Built on mRNA, the technology behind its covid vaccine. The pipeline pushes the same platform into further vaccines and into oncology.
Full MRNA profile →Neurocrine BiosciencesNBIX
Ingrezza for tardive dyskinesia, plus a wider neurology and endocrine portfolio.
Full NBIX profile →More MRNA & NBIX comparisons
Other head-to-heads in the Biotech & innovation segment.
See where MRNA and NBIX sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →